Bethesda III and IV Thyroid Nodules Managed Nonoperatively After Molecular Testing With Afirma GSC or Thyroseq v3
Authors:
- Na Eun KimNKNa Eun Kim
- Rajam S RaghunathanRRRajam S Raghunathan
- Elena G HughesEHElena G Hughes
- Xochitl R LongstaffXLXochitl R Longstaff
- Shanpeng LiSLShanpeng Li
- Yaroslav A GofnungYGYaroslav A Gofnung
- Pouyan FaminiPFPouyan Famini
- James X WuJWJames X Wu
- Michael W YehMYMichael W Yeh
- Masha J LivhitsMLMasha J Livhits
Open Access
- 30 March 2023
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 108 (9) , e698-e703
Abstract
Context: Molecular testing has improved risk stratification and increased nonoperative management for patients with indeterminate thyroid nodules, but data on the long-term outcomes of current molecular tests Afirma Gene Sequencing Classifier (GSC) and Thyroseq v3 are limited. Objective: To determine the rate of delayed operation and the false negative rate of the Afirma GSC and Thyroseq v3 in Bethesda III and IV thyroid nodules. Methods: Prospective follow-up of a single center, randomized, clinical trial comparing the performance of Afirma GSC and Thyroseq v3 in the diagnosis of indeterminate thyroid nodules at the University of California, Los Angeles (UCLA). Consecutive participants who underwent thyroid biopsy in the UCLA health system with Bethesda III and IV cytology from August 2017 to November 2019. The main outcome measure was false negative rate of molecular testing. Results: Of 176 indeterminate nodules with negative or benign molecular test results, 14 (8%) nodules underwent immediate resection, with no malignancies found on surgical pathology. Nonoperative management with active surveillance was pursued for 162 (92%) nodules with benign or negative test results. The median surveillance was 34 months (range 12-60 months), and 44 patients were lost to follow-up. Of 15 nodules resected during surveillance, 1 malignancy was found (overall false negative rate of 0.6%). This was a 2.7 cm minimally invasive Hurthle cell carcinoma that initially tested negative with Thyroseq v3 and underwent delayed resection due to sonographic growth during surveillance. Conclusions: The majority of Bethesda III/IV thyroid nodules with negative or benign molecular test results are stable over 3 years of follow-up. These findings support the high sensitivity of current molecular tests and their role in ruling out malignancy in indeterminate thyroid nodules.Keywords
This publication has 13 references indexed in Scilit:
- Outcomes of Indeterminate Thyroid Nodules Managed Nonoperatively after Molecular TestingThe Journal of Clinical Endocrinology & Metabolism, 2020
- The Clinical Utility of Molecular Testing in the Management of Thyroid Follicular Neoplasms (Bethesda IV Nodules)Annals of Surgery, 2020
- Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate CytologyJAMA Oncology, 2019
- Interinstitutional variation in predictive value of the ThyroSeq v2 genomic classifier for cytologically indeterminate thyroid nodulesSurgery, 2019
- Performance of a Genomic Sequencing Classifier for the Preoperative Diagnosis of Cytologically Indeterminate Thyroid NodulesJAMA Surgery, 2018
- Gene Expression Classifier vs Targeted Next-Generation Sequencing in the Management of Indeterminate Thyroid NodulesThe Journal of Clinical Endocrinology & Metabolism, 2018
- Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodulesCancer, 2018
- Impact of the Multi-Gene ThyroSeq Next-Generation Sequencing Assay on Cancer Diagnosis in Thyroid Nodules with Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance CytologyThyroid®, 2015
- Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next‐generation sequencing assayCancer, 2014
- Preoperative Diagnosis of Benign Thyroid Nodules with Indeterminate CytologyNew England Journal of Medicine, 2012